Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares gained 3.96% to $7.59. The company on Apr. 2 announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. Mr. Cole is a seasoned pharmaceutical executive with more than 25 years of industry experience and a deep background in rare and orphan pharmaceutical markets. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), shares after opening at $7.02 moved to $7.05 on last trade day and at the end of the day closed at $6.69. Company price to sales ratio in past twelve months was calculated as 27.34 and price to cash ratio as 5.26. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), showed a negative weekly performance of 8.36%.
Inovio Pharmaceuticals (NYSE:INO) was the recipient of a large growth in short interest in January. As of March 31st, there was short interest totalling 28,233,502 shares, a growth of 16.6% from the March 14th total of 24,207,003 shares, Analyst Ratings News reports. Approximately 12.5% of the company’s stock are sold short. Based on an average trading volume of 10,185,974 shares, the short-interest ratio is presently 2.8 days. Inovio Pharmaceuticals Inc (NYSEMKT:INO), shares fell 2.62% in last trading session and ended the day on $2.60. Inovio Pharmaceuticals Inc (NYSEMKT:INO), return on equity ratio is recorded as -144.40% and its return on assets is -92.70%. Inovio Pharmaceuticals Inc (NYSEMKT:INO), yearly performance is 381.48%.
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by Jefferies Group from $26.00 to $38.00. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), shares moved up 3.03% in last trading session and was closed at $18.36, while trading in range of $ 15.64 – 18.36. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), year to date (YTD) performance is -26.53%.
Organovo Holdings (NASDAQ:ONVO) CEO Keith Murphy sold 100,000 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $10.86, for a total value of $1,086,000.00. Following the completion of the sale, the chief executive officer now directly owns 6,101,748 shares of the company’s stock, valued at approximately $66,264,983. Organovo Holdings Inc (NYSEMKT:ONVO), weekly performance is -17.00%. On last trading day company shares ended up $6.64. Organovo Holdings Inc (NYSEMKT:ONVO), distance from 50-day simple moving average (SMA50) is -26.22%.
Leave a Reply